Supplementary Table S1. Univariate analysis of impact factors for ypN+ in the whole, breast pathological complete remission (pCR) and breast non-pCR population

Factors	Whole	Breast pCR	Breast non-pCR
Age (≥50 vs <50)	0.738	0.456	0.979
Menstruation (post vs premenopausal)	0.829	0.854	0.960
Clinical stage	**<0.001**	**<0.001**	**<0.001**
cT1-2N0	Ref	Ref	Ref
cT1-2N1	**<0.001**	**<0.001**	**<0.001**
LABC	**<0.001**	**<0.001**	**<0.001**
Histology (other invasive vs IDC)	0.305	0.572	0.449
Tumor grade (III vs I-II)	**0.033**	0.767	**0.003**
ER (positive vs negative)	**<0.001**	0.329	**0.001**
PR (positive vs negative)	**<0.001**	**0.034**	**0.002**
HER2 (positive vs negative)	**<0.001**	**0.004**	**<0.001**
Ki67 (≥14% vs <14%)	0.080	0.461	0.684
Molecular subtype	**<0.001**	0.081	**<0.001**
Luminal A	Ref	Ref	Ref
Luminal B (HER2-)	0.780	0.927	0.328
Luminal B (HER2+)	**0.019**	0.229	0.270
HER2-amplified	**0.001**	0.269	0.052
TNBC	0.141	0.816	0.521
NAC regimens	**<0.001**	0.459	**<0.001**
Containing A	Ref	Ref	Ref
Containing T	0.201	0.280	0.597
A+T combination	**0.014**	0.214	**0.009**
Neoadjuvant targeted therapy (Yes vs No)	**<0.001**	**0.017**	**<0.001**
NAC cycles (>6 vs 4-6)	0.400	0.058	0.205
Breast pCR (Yes vs No)	**<0.001**	/	/

Abbreviations: IDC, invasive ductal carcinoma; ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor 2; TNBC, triple negative breast cancer; NAC, neoadjuvant chemotherapy; A, anthracyclines; T, taxanes; LABC, locally advanced breast cancer; pCR, pathological complete remission.